News Archive

I don’t think I’ve ever (in 20+ years of writing) reprinted a press release verbatim. Often I don’t even get to the end of them because of all the PR speak. However, today the Mayo Clinic sent out this list. It is concise, compelling and I can’t think of any way to improve it. The 10 ways the human genome map can affect diagnosis and treatment is an important reminder that we have come a long way in a short time, and that healthcare in the United States is not all about arguing about who gets care and who pays for it.

In case you had any doubts that the $3.8 billion investment in the genome mapping project was worth it, consider these 10 advancements compiled by the Mayo Clinic.

United Therapeutics Corporation announced today that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the new drug application (NDA) for treprostinil diolamine extended release tablets (oral treprostinil) for the treatment of pulmonary arterial hypertension. The FDA classified the resubmission as a complete, class 2 response to its March 22, 2013 complete response letter, and set a user fee goal date of February 16, 2014.

About United TherapeuticsUnited Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Normal adult cells have been reprogrammed to become stem cells inside live mice for the first time.

As stem cells can be coaxed into developing into almost any kind of cell, being able to prompt this behaviour in the body could one day be used to repair ailing organs including the heart, liver, spinal cord and pancreas.

“By doing it in situ, the cells are already there in the tissue, in the right position,” says Manuel Serrano at the Spanish National Cancer Research Centre in Madrid, and co-leader of the new work.

The University of Maryland and Northrop Grumman will jointly announce the launch of the Advanced Cybersecurity Experience for Students (ACES), the nation’s first cybersecurity honors program for undergraduates, at a special event on Wednesday, September 25, 2013, from 10:30-11:30 a.m. in the Stamp Student Union Atrium on the University of Maryland College Park Campus.

The ACES program is designed to educate future leaders in the field of cybersecurity through rigorous, hands-on learning experiences, an intensive interdisciplinary curriculum, collaborative projects, and professional insight from industry and business leaders. The four-year honors program offers students a living-learning experience, giving them the opportunity to collaborate and work closely together as they pursue their advanced program of study in cybersecurity. The inaugural ACES cohort is comprised of 57 students. The ACES program is supported by a major grant from Northrop Grumman. For more information about the program, visit aces.umd.edu.

The INNo program trains research scientists in the entrepreneurial skills needed to bring technology inventions and services to the healthcare market.

Participants in the INNo program learn to:

• Identify and evaluate the commercial potential of intellectual property
• Understand the business fundamentals related to technology start-ups
• Create a value proposition and business concept for a new product, platform, or service
• Articulate investment opportunities persuasively to potential investors and partners
• Develop a network of resources in the Maryland entrepreneurial community

Roche’s move to skip over Inovio’s (NYSE: INO) late stage drugs for cervical cancer and Hepatitis C and make a beeline for its preclinical DNA vaccines for prostate cancer and Hep B was initially a little puzzling. Investors have preferred to park their money further upstream when products are in the clinic and they’ve been derisked. Big pharma is always looking for ways to take costs out of research and development. But the prospect of utilizing new technology with the potential to improve treatment is appealing for drug developers that want to build up and strengthen their drug pipeline.

Two Washington region tech companies — Clarabridge Inc. and Virtustream Inc. — rolled out a combined $120 million in funding on Tuesday, another sign of an improving venture ecosystem. Both rank among the Top 10 biggest D.C. Tech investments thus far in 2013

Not all of the fundings on this list qualify as “venture,” of course. Some of the larger ones could just as easily be called private equity, or at least the hybrid term “growth.” Like we see with Clarabridge’s $80 million, big-ticket financings like these often go partly toward cashing out earlier investors. And not all came from traditional VC. In Virtustream’s case, the entire $40 million Series D round came from a single corporate source: SAP AG.

The Abell Foundation underwrote a comparison of Baltimore’s innovation ecosystem with that of Boston. Sean Pool and Matt Van Itallie, of Canterbury Road Partners, undertook the work and their report is telling of the challenges in front of us, but also reveals great promise of the resources we already have and what Baltimore’s innovation ecosystem can become. The full report can be found on the Abell Foundation website.

This video is the first in a series about Startup Shell, the first student-founded, student-run venture incubator at the University of Maryland.

The Startup Shell is a vibrant co-working space at UMD where talented students guide their colleagues through ideation, research and development, product prototyping, business model creation and more.

Startup Shell is located in the Technology Advancement Program (TAP) incubator, an initiative of the Maryland Technology Enterprise Institute (Mtech) in the A. James Clark School of Engineering.

Target has joined one of the growing trends in healthcare: innovation challenges. It announced on Monday two contests: one will seek a solution that helps people make positive lifestyle and prevention choices, while the other will gather ways to help people live well with a chronic condition.

The Target Simplicity Challenge will reward the creators of the winning ideas $25,000 apiece, their own Target-branded flip camera, and a chance to partner with Target to develop the concepts. The deadline for ideas is Oct. 24 and winners will be announced by January.